Podría estar lista el próximo mes. The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month. A pesar de las ...

NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

For RNA viruses that mutate frequently ... We have seen encouraging data with Moderna’s personalised melanoma vaccine and BioNTech is due to present data on its mRNA-shared antigen melanoma ...

Her patents - for application of non-immunogenic, modified RNA - co-invented with Drew Weissman were used to create the FDA-approved COVID-19 mRNA vaccines by BioNTech/Pfizer and Moderna to fight the ...

Catching the virus that causes COVID-19 or getting a COVID-19 vaccination gives you protection, also called immunity, from the virus. But over time, that protection seems to ...

Their technology is based on synthetic messenger RNA – short for ribose ... opportunities to take on the coronavirus vaccine challenge were huge for BioNTech, which only went public on the ...

The global lipid nanoparticles market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a ...

HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT (Prepositioning Optimized Strategies for ...

HDT bio's Rapid-Response Roadmap for RNA vaccines (R 4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ -- HDT Bio Corp., a clinical-stage ...